Related Experiment Video

Updated: May 31, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Deciphering the Structural Basis of Allosteric Inhibition of Mutant Epidermal Growth Factor Receptor and

Sapna Pal1, Debasisa Mohanty1

  • 1Bioinformatics Center, BRIC-National Institute of Immunology, New Delhi 110067, India.

Computational and Structural Biotechnology Journal
|May 29, 2026
PubMed

Insights

This study used molecular dynamics simulations to understand how allosteric inhibitors target mutant epidermal growth factor receptor (EGFR) in non-small cell lung cancer. Findings reveal a mechanism for stabilizing the inactive EGFR state, aiding the design of new drugs to overcome resistance.

Area of Science:

  • Biochemistry and Molecular Biology
  • Computational Chemistry
  • Pharmacology

Background:

  • The L858R/T790M mutation in epidermal growth factor receptor (EGFR) causes resistance to existing tyrosine kinase inhibitors (TKIs).
  • Allosteric inhibitors offer a promising alternative by stabilizing the inactive conformation of EGFR, but their mechanism requires detailed understanding.

Purpose of the Study:

  • To elucidate the structural and conformational basis of allosteric inhibition in mutant EGFR (EGFRL858R/T790M).
  • To explore the role of molecular dynamics (MD) simulations in designing allosteric inhibitors that stabilize the inactive EGFR state.
  • To develop and validate a computational screening protocol for identifying novel allosteric inhibitors.

Main Methods:

  • Microsecond-scale molecular dynamics (MD) simulations of wild-type and mutant apo-EGFR.
  • MD simulations of EAI001-bound EGFRL858R/T790M to analyze inhibitor effects.
  • Virtual screening of an allosteric TKI library using a machine-learning affinity predictor.
  • Free energy calculations (MM/GBSA) to evaluate top-scoring drug candidates.

Main Results:

  • MD simulations revealed how mutations shift EGFR towards an active state and how EAI001 binding suppresses active-like conformations.
  • Inhibitor binding modulates key structural elements like the αC-helix and activation loop, stabilizing the inactive EGFR state.
  • A validated computational approach identified potential allosteric inhibitors predicted to be more potent than EAI001.

Conclusions:

  • The study elucidates the mechanism of allosteric inhibition for mutant EGFR, highlighting the importance of stabilizing the inactive state.
  • MD simulations integrated with machine learning provide a powerful framework for discovering next-generation EGFR inhibitors.
  • This approach offers a strategy to overcome TKI resistance in non-small cell lung cancer.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.